SCHEMBL11029618

SCHEMBL11029618

O=Cc1cn(C(=O)O)c2ncccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
HSP90AA1 P07900 1/20 0.50
IDO1 P14902 1/20 0.50
RAB9A P51151 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ELANE P08246 14/20 0.43
KDM6B O15054 1/20 0.40
KDM6A O15550 1/20 0.40
TET3 O43151 1/20 0.40
KDM4A O75164 1/20 0.40
KDM4B O94953 1/20 0.40
KDM5C P41229 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
TET2 Q6N021 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.40
TET1 Q8NFU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2491259 0.86 ELANE (0.59) KMT2AKDM4EL3MBTL1MEN1NPC1
SCHEMBL3707206 0.80 ELANE (0.44) KMT2AKDM4EL3MBTL1MEN1NPC1
SCHEMBL29443982 0.80 ELANE (0.44) KMT2AKDM4EL3MBTL1MEN1NPC1
SCHEMBL28673352 0.78 ELANE (0.49) KDM4EL3MBTL1ELANEKDM6BKDM6A
SCHEMBL28994902 0.78 ELANE (0.59) KMT2AKDM4EL3MBTL1MEN1HSP90AA1
SCHEMBL30069016 0.78 ELANE (0.49) KDM4EL3MBTL1ELANEKDM6BKDM6A
SCHEMBL11027996 0.76 ELANE (0.48) KDM4EL3MBTL1NPC1RAB9AELANE
SCHEMBL15902268 0.76 KDM4E (0.47) KMT2AKDM4EL3MBTL1MEN1NPC1
SCHEMBL970742 0.76 ALDH1A1 (0.54) KMT2AKDM4EL3MBTL1MEN1NPC1
SCHEMBL12146934 0.76 KDM4E (0.46) KMT2AKDM4EL3MBTL1MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 US disclosed
CN-118139864-A New compounds 西特瑞治疗有限公司 2024-06-04 CN disclosed
US-20210403470-A1 NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS WATKINS EDMOND BLAKE (US) 2021-12-30 US disclosed
US-11117893-B2 Methods for preparation of substituted pyridines and related novel compounds UNION UNIVERSITY (US) 2021-09-14 US disclosed
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-02-23 US disclosed
CN-110461849-B CSF1R inhibitor and preparation method and application thereof 上海和誉生物医药科技有限公司 2020-09-01 CN disclosed
US-20200095245-A1 NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS UNION UNIVERSITY 2020-03-26 US disclosed
EP-3617192-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2020-03-04 EP disclosed
US-10550123-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2020-02-04 US disclosed
CN-110461849-A A kind of CSF1R inhibitor and its preparation method and application ABBISKO THERAPEUTICS CO LTD 2019-11-15 CN disclosed
US-20190337954-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2019-11-07 US disclosed
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-10-01 US disclosed
EP-2760831-B1 VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2019-08-07 EP disclosed
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-13 US disclosed
EP-3344615-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2018-07-11 EP disclosed
WO-2017037116-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-09 WO disclosed
EP-2760831-A1 VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven (BE) 2014-08-06 EP disclosed
US-20140213586-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2014-07-31 US disclosed
WO-2013045516-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2013-04-04 WO disclosed
US-20120190701-A1 RENIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428026-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT KMT2A 208/4885KDM4E 426/4885L3MBTL1 4684/4885
US-20210403470-A1 NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS WEE1, WEE2, THEM6 KMT2A 2316/4885KDM4E 2177/4885L3MBTL1 4355/4885
US-20140213586-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 KMT2A 2425/4885KDM4E 1372/4885L3MBTL1 2136/4885
US-11117893-B2 Methods for preparation of substituted pyridines and related novel compounds NNMT, CYP4F3, AGPS KMT2A 2314/4885KDM4E 2302/4885L3MBTL1 4409/4885
US-20120190701-A1 RENIN INHIBITORS REN, ACE, AGTR1 KMT2A 4131/4885KDM4E 3912/4885L3MBTL1 3966/4885
US-20190337954-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 KMT2A 2425/4885KDM4E 1372/4885L3MBTL1 2136/4885
US-20200095245-A1 NOVEL METHODS FOR PREPARATION OF SUBSTITUTED PYRIDINES AND RELATED NOVEL COMPOUNDS WEE1, WEE2, THEM6 KMT2A 2316/4885KDM4E 2177/4885L3MBTL1 4355/4885
US-20180258044-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRDT KMT2A 208/4885KDM4E 426/4885L3MBTL1 4684/4885
US-10550123-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 KMT2A 2425/4885KDM4E 1372/4885L3MBTL1 2136/4885
US-10927080-B2 Pyridinone dicarboxamide for use as bromodomain inhibitors BRD4, BRD3, BRDT KMT2A 208/4885KDM4E 426/4885L3MBTL1 4684/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 KMT2A 2425/4885KDM4E 1372/4885L3MBTL1 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.